Should Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?

Senturk, Aysegul; YILMAZEL UÇAR, Elif; BERK, SERDAR; ÖZLÜ, TEVFİK; Altinsoy, Bulent; Dabak, Gul; Cakir, Ebru; Kadioglu, Esra; ŞEN, HADİCE; Ozsu, Savas

doi:10.1177/1076029614564863

Should Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?

Senturk A., YILMAZEL UÇAR E., BERK S., ÖZLÜ T., Altinsoy B., Dabak G., ...Daha Fazla

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.22, sa.4, ss.395-399, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 4
Basım Tarihi: 2016
Doi Numarası: 10.1177/1076029614564863
Dergi Adı: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.395-399
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Purpose: The role of low-molecular-weight heparin (LMWH) in managing nonmassive pulmonary embolism (PE) is well known. In unstable cases, especially after thrombolytic therapy for massive PE, unfractionated heparin (UFH) is preferred for PE management. This study aimed to investigate the effectiveness and safety of LMWH after thrombolytic therapy.